SCHEMBL720269

SCHEMBL720269

COc1ccc2cc(C(Nc3ccc(C(=O)O)cc3)C3CCCCC3)oc2c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.50
KDM4E B2RXH2 4/20 0.50
RAB9A P51151 3/20 0.50
HPGD P15428 2/20 0.50
HSD17B10 Q99714 1/20 0.50
RCE1 Q9Y256 1/20 0.46
MAPT P10636 3/20 0.45
SLC16A3 O15427 1/20 0.43
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
MAPK1 P28482 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
HPGDS O60760 3/20 0.41
NPC1 O15118 2/20 0.41
MAOB P27338 2/20 0.41
GAA P10253 2/20 0.41
AKR1C3 P42330 1/20 0.40
AKR1C2 P52895 1/20 0.40
POLB P06746 2/20 0.40
AKR1B10 O60218 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL718231 0.92 ALDH1A1 (0.50) ALDH1A1KDM4ERAB9AHPGDHSD17B10
SCHEMBL720105 0.88 ALDH1A1 (0.47) ALDH1A1KDM4ERAB9AHPGDHSD17B10
SCHEMBL720111 0.86 ALDH1A1 (0.43) ALDH1A1KDM4ERAB9AHPGDHSD17B10
SCHEMBL719470 0.83 RCE1 (0.53) KDM4ERAB9ARCE1MEN1KMT2A
SCHEMBL717279 0.82 GCG (0.44) ALDH1A1KDM4ERAB9AHPGDHSD17B10
SCHEMBL720543 0.80 NPC1 (0.52) ALDH1A1KDM4ERAB9ARCE1MAPT
SCHEMBL721051 0.79 NPC1 (0.45) ALDH1A1KDM4ERAB9AHPGDHSD17B10
SCHEMBL718424 0.79 HSD17B10 (0.41) ALDH1A1KDM4ERAB9AHPGDHSD17B10
SCHEMBL718278 0.77 NPC1 (0.43) ALDH1A1KDM4ERAB9AHPGDHSD17B10
SCHEMBL718794 0.75 NR1H4 (0.45) ALDH1A1RCE1MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 US disclosed
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 US disclosed
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 US disclosed
EP-2251326-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053173-A1 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP ALDH1A1 504/4885KDM4E 1907/4885RAB9A 2454/4885
US-20120270865-A2 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP ALDH1A1 504/4885KDM4E 1907/4885RAB9A 2454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.